한국형 우울장애 약물치료 알고리듬 2025 (III): 소아·청소년

Abstract

Objectives The Korean Medication Algorithm Project for Depressive Disorder 2025 (KMAP-DD 2025) represents a revision of the prior iterations. The primary objective of the present study was to refine treatment guidelines for major depressive disorders (MDDs) in child and adolescent populations. Methods The survey instrument comprised 21 questionnaires specifically tailored for children and adolescents. A total of 42 out of 70 experts in child and adolescent psychiatry completed and returned the survey questionnaires. Results Antidepressant (AD) monotherapy was identified as the first-line treatment option for MDD of mild-to-moderate severity. For severe MDD without psychotic features in children and adolescents, both AD monotherapy and AD augmentation with atypical antipsychotics (AAPs) were recommended as first-line treatments. In cases of MDD with psychotic features, AD augmentation with AAPs was the preferred first-line treatment strategy. Conclusion We have developed a treatment algorithm specifically for child and adolescent populations with depressive disorders, offering enhanced specificity compared to the KMAP-DD 2021. It is anticipated that this algorithm will furnish clinicians with valuable information and facilitate the management of depressive disorders in children and adolescents.